Verastem Oncology Announces Design for Confirmatory Trial of

Randomized Phase 3 Trial (RAMP 301) Will Evaluate the Combination of Avutometinib and Defactinib vs Standard of Care Treatment; Study to Commence in 2H 2023Recently Published Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45%, and Manageable Safety and Tolerability Profile with the Combination...

Related Keywords

United States , London , City Of , United Kingdom , Berlin , Germany , Dan Calkins , Elisa Buffington , Brian Stuglik , Nate Liabraaten , Rachel Grisham , Susana Banerjee , National Cancer Institute , Institute Of Cancer Research , European Society Of Gynaecological Oncology , Partners Program , Corporate Communications , Chugai Pharmaceutical Co Ltd , Drug Administration , Company Annual Report On Form , Foundation Inc , Team Leader In Women Cancers , Secura Bio Inc , European Network Of Gynaecological Oncological Trial , Company Intends To File For Accelerated , Memorial Sloan Kettering Cancer Center , Exchange Commission , Company Phase , European Network For Gynaecological Oncological Trial , Amgen , Raf And Mek Program , Randomized Phase , Will Evaluate , Care Treatment , Npublished Data , Objective Response Rate , Manageable Safety , Tolerability Profile , Combination Based , Mature Data , Verastem Oncology , Chief Executive Officer , European Network , Gynaecological Oncological Trial , Blinded Independent Central , Section Head , Ovarian Cancer , Gynecologic Medical Oncology , Consultant Medical Oncologist , Royal Marsden , Team Leader , Cancer Research , Breakthrough Therapy , European Society , Gynaecological Oncology , Secura Bio , Annual Report ,